FUNCTIONAL ALTERATIONS OF ADIPOSE-DERIVED MESENCHYMAL STEM CELLS ISOLATED FROM DIABETIC SUBJECTS - A SYSTEMATIC REVIEW

• Published in: Cytotherapy (Oxford, England) Vol. 23; no. 4; p. 16
• Main Authors: Côrtes, DA, de Carvalho, JL
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 01.04.2021
• Subjects: Advanced Basic Science; Other
• ISSN: 1465-3249
• DOI: 10.1016/j.jcyt.2021.02.049

While healthy adipose-derived mesenchymal stem cells (ADMSCs) may confer therapeutic benefits to treated subjects, the dysfunction of endogenous ADMSCs in diabetes is thought to contribute to further complications of the disease. However, little is known about how diabetes impacts specific phenotypes of ADMSCs. The purpose of this systematic review is to provide comprehensive information about the impact of diabetes mellitus on adipose- derived mesenchymal stem cell function, elucidating the behavior of cells extracted from diabetic humans and animal models (dADMSCs) compared to healthy counterparts (nADMSCs). A PubMed literature search, held on November 11th, 2020, returned a total of 470 articles, of which 109 met the inclusion criteria based on their title and abstract. After full-text assessment, 32 articles were selected for final inclusion and gathered into 7 categories based on the properties of dADMSCs addressed: proliferation; viability; oxidation levels; stemness; multipotency; immunoregulatory and proangiogenic capacity. According to the categories established, the results show that the proliferation rate of dADMSCs is impaired, but mixed results regarding the effect of diabetes on ADMSC viability, oxidation levels, stemness, differentiation capacity, immunoregulation and proangiogenesis were observed and require further investigation. The dissonance between published results and the lack of more robust data may be explained, at least in part, to different cell donor age, disease severity, diabetes type, gender, as well as diverse cell culture conditions and experimental settings, citing but a few uncontrolled factors detected. Based on this review, we conclude that the lower renewal capacity of dADMSC may possibly compromise the interest in its therapeutic use, even in autologous settings. Nevertheless, considering the unclear impact of diabetes over the other ADMSC properties analyzed, the therapeutic application of dADMSC may still be considered as a possible option, justifying further investigation. Funding sources: CNPq, CAPES and FAPDF.